This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke (ARTSS-2)

This study has been terminated.
(The study was halted prematurely at 90 of 105 planned patients due to the beneficial results of embolectomy clinical trials.)
Sponsor:
Collaborator:
The University of Texas Health Science Center, Houston
Information provided by (Responsible Party):
Andrew D. Barreto, MD, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT01464788
First received: November 1, 2011
Last updated: March 31, 2017
Last verified: March 2017
November 1, 2011
March 31, 2017
October 2011
June 11, 2015   (Final data collection date for primary outcome measure)
  • Number of Participants With 0 or 1 on Modified Rankin Scale [ Time Frame: 90 days ]
    Excellent functional outcome as measured by the number of patients with a 0 or 1 on the modified Rankin Scale (mRS) at day 90 as assessed by study personnel blinded to treatment.
  • Number of Participants With Symptomatic Intracranial Hemorrhage Within 48 Hours of tPA Administration [ Time Frame: 48-hours ]
    Symptomatic intracranial hemorrhage (sICH) is defined as any evidence of bleeding on CT scan that in the opinion of the treating physician and/or an independent safety monitor is associated with a clinically significant neurological worsening. A four or more point increase in the NIHSS score from baseline (or last score obtained prior to blood found on CT scan) to subsequent CT scan at the time of potential worsening can be used as a guide by the clinical investigator or safety monitor for what represents a significant worsening in neurologic status but sICH can include any worsening deemed significant by the clinical investigator or independent safety monitor.
Percentage of patients with 0 or 1 on Modified Rankin Scale [ Time Frame: 90 days ]
Excellent functional outcome as measured by the percentage of patients with a 0 or 1 on the modified Rankin Scale (mRS) at day 90 as assessed by study personnel blinded to treatment.
Complete list of historical versions of study NCT01464788 on ClinicalTrials.gov Archive Site
Not Provided
  • Incidence of hemorrhage [ Time Frame: 90 days ]

    1) Safety as measured by the incidence of:

    1. Symptomatic intracranial hemorrhage (sICH);
    2. Parenchymal Hemorrhage 2 (PH-2);
    3. Major systemic hemorrhage.
  • Rates of recanalization [ Time Frame: 2 hours ]
    Rates and completeness of arterial recanalization assessed at baseline and 2-3 hours by Transcranial Doppler ultrasound (TCD) or CT-Angiogram (CTA).
  • Improvement in neurological deficits [ Time Frame: 90 days ]
    Neurological deficits improvement from baseline to 2 hours, 24 hours, end of Argatroban infusion, Day 7/discharge and day 90 as measured by NIHSS.
  • Cost effectiveness [ Time Frame: 90 days ]
    Cost and cost-effectiveness analysis Medical costs associated with each treatment Incremental cost-effectiveness ratio (change in cost divided by quality of life gained)
Not Provided
Not Provided
 
Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke
ARTSS-2: A Pilot, Phase 2b, Randomized, Multi-center Trial of Argatroban in Combination With Recombinant Tissue Plasminogen Activator for Acute Stroke
Randomized controlled clinical trial to estimate overall treatment benefit (improvement in disability) among stroke patients treated with rt-PA who are randomized to also receive either low-dose Argatroban, high-dose Argatroban or neither.

Recombinant tissue plasminogen activator (rt-PA), the only proven treatment for acute ischemic stroke, fails to reperfuse brain in most patients with large thrombi. In our Phase 2a low-dose safety study (n=65), the two drugs appeared safe when delivered concomitantly and recanalization rates were greater than historical controls. This study will provide evidence-based hypotheses and data needed to design a larger definitive trial.

The purpose of this trial is to estimate overall treatment benefit (improvement in disability) among stroke patients treated with rt-PA who are randomized to also receive either low-dose Argatroban, high-dose Argatroban or neither.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Outcomes Assessor
Primary Purpose: Treatment
Ischemic Stroke
  • Drug: Low Dose Argatroban
    100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
    Other Name: Argatroban
  • Drug: High Dose Argatroban
    100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
    Other Name: Argatroban
  • Drug: rt-PA (alteplase)
    rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
  • Experimental: Low dose Argatroban + rt-PA (alteplase)

    100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours

    and

    rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour

    Interventions:
    • Drug: Low Dose Argatroban
    • Drug: rt-PA (alteplase)
  • Experimental: High dose Argatroban + rt-PA (alteplase)

    100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours

    and

    rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour

    Interventions:
    • Drug: High Dose Argatroban
    • Drug: rt-PA (alteplase)
  • Active Comparator: rt-PA (alteplase)
    rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
    Intervention: Drug: rt-PA (alteplase)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
90
June 11, 2015
June 11, 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Disabling Ischemic stroke symptoms with onset < 3 hours treated with IV rt-PA by local standards*.

    * or ≤ 4.5 hours according to local standard of care.

  • NIHSS ≥ 10* or any NIHSS with an intracranial clot should be demonstrated on neurovascular imaging (TCD or CTA) in any one of the following areas: distal internal carotid artery (ICA) carotid artery (CA), middle cerebral artery (MCA - M1 or M2), posterior cerebral artery (PCA - P1 or P2), distal vertebral or basilar artery.
  • TCD criteria: Thrombolysis in brain ischemia (TIBI) 0, 1, 2 or 3 - CT-Angiogram: thrombolysis in myocardial ischemia (TIMI) 0 or 1 * NIHSS ≥ 10, demonstration of clot on neuroimaging is not necessary (i.e., enrollment can proceed with non-contrast head CT alone), but if performed, a clot must be demonstrated.
  • For those patients who will undergo repeat CT-Angiogram at 2-3 hours, estimated glomerular filtration rate (eGFR) must be ≥ 60 mL/min/1.73m2.
  • Females of childbearing potential must have a negative serum pregnancy test (HCG) prior to the administration of trial medication.
  • Signed (written) informed consent by the patient or the patient's legal representative and/or guardian.

Exclusion Criteria:

  • Patients whom the treating physician is planning (or could plan) to treat with intra-arterial thrombolysis or other endovascular procedures (i.e., mechanical clot retrieval) aimed at recanalization.
  • Evidence of intracranial hemorrhage (ICH) on baseline CT scan or diagnosis of a non-vascular cause of neurologic deficit.
  • National institute health stroke scale (NIHSS) Level of Consciousness score (1a) ≥ 2.
  • Pre-existing disability with mRS ≥ 2.
  • CT scan findings of hypoattenuation of the x-ray signal (hypodensity) involving ≥ 1/3 of the MCA territory.
  • Any evidence of clinically significant bleeding, or known coagulopathy.
  • INR >1.5.
  • Patients with an elevated activated partial thromboplastin time (aPTT) greater than the upper limit of normal
  • Patients currently, or within the previous 24 hours, on an oral direct thrombin inhibitor (i.e., dabigatran).
  • Heparin flush required for an IV line. Line flushes with saline only.
  • Any history of intra-cranial hemorrhage, known arteriovenous -malformation or unsecured cerebral aneurysms.
  • Significant bleeding episode [e.g. gastrointestinal (GI) or urinary tract] within the 3 weeks before study enrollment.
  • Major surgery or serious trauma in last 2 weeks.
  • Patients who have had an arterial puncture at a non-compressible site, biopsy of parenchymal organ, or lumbar puncture within the last 2 weeks.
  • Previous stroke, myocardial infarction (MI), post myocardial infarction pericarditis, intracranial surgery, or significant head trauma within 3 months.
  • Uncontrolled hypertension [Systolic blood pressure (SBP) > 185 mmHg or diastolic blood pressure (DBP) >110 mmHg] that does not respond to intravenous anti-hypertensive agents.
  • Surgical intervention (any reason) anticipated within the next 48 hours.
  • Known history of clinically significant hepatic dysfunction or liver disease - including a current history of alcohol abuse.
  • Abnormal blood glucose <50 mg/dL (2.7 mmol/L).
  • History of primary or metastatic brain tumor.
  • Current platelet count < 100,000/mm3.
  • Life expectancy < 3 months.
  • Patient who, in the judgment of the investigator, needs to be on concomitant (i.e., during the Argatroban infusion) anticoagulants other than Argatroban, including any form of heparin, unfractionated heparin (UFH), low molecular weight heparin (LMWH), defibrinogenating agent, dextran, other direct thrombin inhibitors or thrombolytic agents, glycoprotein llb/llla (GPIIb/IIIa) inhibitor or warfarin.
  • Participated in any investigational study within 30 days before the first dose of study medication.
  • Known hypersensitivity to Argatroban or its agents.
  • Additional exclusion criteria if patient presents between 3-4.5 hours:

    1. Age >80
    2. Currently taking oral anticoagulants (regardless of INR)
    3. A history of stroke and diabetes.
    4. NIHSS > 25.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01464788
HSC-MS-11-0464
Yes
Not Provided
Not Provided
Andrew D. Barreto, MD, The University of Texas Health Science Center, Houston
Andrew D. Barreto, MD
The University of Texas Health Science Center, Houston
Principal Investigator: Andrew Barreto, MD The University of Texas Health Science Center, Houston
The University of Texas Health Science Center, Houston
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP